Hanmi Pharm has made a provisional announcement that it attained 1.016 trillion won in sales and 83.6 billion won in operating profit last year. The company's series of successes in technology exports have resulted in a revenue recovery of 1 trillion won in three years since it surpassed 1 trillion won in sales in 2015.
It is meaningful that Hanmi Pharm achieved 1 trillion won in sales with its own medicines. About 93.3% of the sales of Hanmi Pharm medicines are self-developed. In the case of its competitors, 45 to 75 percent of their sales are products from foreign pharmaceutical companies.
All of the top 10 products in the sales of Hanmi Pharm are new drugs or complex products that are developed by the company such as Amozaltan (47.4 billion won) and Esomezol (26.4 billion won).
In particular, sales and operating profit of Hanmi Pharm rose by 26.3 percent year-on-year and 1,025.8 percent to 293.7 billion won and 15.9 billion won, respectively in the fourth quarter of last year.
Despite an increase in labor expenses and R&D costs, the company changed its structure based on its own development products and surpassed the consensus due to profits from technical fees.